Addressing the Commercial Importance of Supplementary Protection Certificates
Hosted By : Andrea CharlesAugust 16, 2011
Rate this Podcast:
(4.0 Stars | 4 Votes)
About this Podcast...
As major patents on blockbuster drugs continue to expire, Chris Hayes, Senior Advisor, Intellectual Property Rights - Launched Products, Lundbeck, and Andrea Charles from Pharma IQ discuss how return-on-investment can be maximised and the key drivers for IP strategy. In this podcast, Hayes shares his thoughts on the commercial importance of Supplementary Protection Certficates (SPCs) and the pros and cons of SPCs versus data protection.
| Have Your Say Rate this feature and give us your feedback in the comments section below |
Rate this Podcast:
(4.0 Stars | 4 Votes)
Events of Interest
-
EU Product Launch – Key Considerations for Successful Niche and Orphan Drug Product Launches
February 9, 2012
Register Now -
Information Governance & eDiscovery for Pharma, Biotech and Medical Devices
London, UK
June 26- 28, 2012 -
Electronic Laboratory Notebooks Online
December 2, 2011
Register Now -
Clinical Trial Supply
Congress Center Basel, Basel, Switzerland
January 30- 1, 2013






Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!